MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling in EGFR-mutated (EGFR(MT)) NSCLC cells treated with OSI, suggesting a role for MERTK activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Dan, Huelse, Justus M., Kireev, Dmitri, Tan, Zikang, Chen, Luxiao, Goyal, Subir, Wang, Xiaodong, Frye, Stephen V., Behera, Madhusmita, Schneider, Frank, Ramalingam, Suresh S., Owonikoko, Taofeek, Earp, H. Shelton, DeRyckere, Deborah, Graham, Douglas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337831/
https://www.ncbi.nlm.nih.gov/pubmed/35708914
http://dx.doi.org/10.1172/JCI150517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9337831/
https://www.ncbi.nlm.nih.gov/pubmed/35708914
http://dx.doi.org/10.1172/JCI150517

Ejemplares similares